Literature DB >> 11310306

AV block and changes in pacing mode during long-term follow-up of 399 consecutive patients with sick sinus syndrome treated with an AAI/AAIR pacemaker.

L Kristensen1, J C Nielsen, A K Pedersen, P T Mortensen, H R Andersen.   

Abstract

This retrospective study included a large cohort of consecutive patients primarily implanted at Skejby University Hospital with an AAI/AAIR pacemaker because of sick sinus syndrome (SSS) from July 1981 to July 1999. The primary aim of the study was to analyze the risk of developing AV block during long-term follow-up. A secondary aim was to study the incidence and reasons for changes in pacing mode caused by other than AV block. A total of 399 patients (231 women, mean age 71 +/- 13.5 years) were identified. Mean follow-up was 4.6 +/- 3.4 years and occurred at death, reoperation with mode change, pacemaker explant, or end of study. During follow-up, 44 patients had a ventricular lead implanted with a mean delay of 2.8 +/- 3.1 years (range 1 day-10.4 years) after the primary implantation. A total of 30 patients received a ventricular lead because of AV block or AF with bradycardia (annual incidence 1.7%). Another 14 patients received a ventricular lead without having documented AV block or AF with pauses (annual incidence 0.8%). The present observational study documents that in patients with SSS treated with AAI/AAIR pacing, AV block requiring implantation of a ventricular lead occurs at a rate of 1.7% per year. It is considered that AAI/AAIR pacing is safe and reliable as treatment for patients with SSS and normal AV conduction.

Entities:  

Mesh:

Year:  2001        PMID: 11310306     DOI: 10.1046/j.1460-9592.2001.00358.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  9 in total

1.  Physiologic pacing: where pacing mode selection reflects the indication.

Authors:  J S Healey; E Crystal; S J Connolly
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

Review 2.  Cardiac pacing strategies and post-implantation risk of atrial fibrillation and heart failure events in sinus node dysfunction patients: a collaborative analysis of over 6000 patients.

Authors:  Shaojie Chen; Zhenglong Wang; Marcio Galindo Kiuchi; Bruno Rustum Andrea; Mitchell W Krucoff; Shaowen Liu; Helmut Pürerfellner
Journal:  Clin Res Cardiol       Date:  2016-02-25       Impact factor: 5.460

3.  Current concepts in pacing 2010-2011: the right and wrong way to pace.

Authors:  Simon Modi; Andrew Krahn; Raymond Yee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-10

4.  Atrial pacing, the forgotten pacing mode.

Authors:  M El Gamal
Journal:  Neth Heart J       Date:  2008-10       Impact factor: 2.380

5.  The usefulness of minimal ventricular pacing and preventive AF algorithms in the treatment of PAF: the 'MinVPace' study.

Authors:  Rick A Veasey; Anita Arya; Nick Freemantle; John Silberbauer; Nikhil R Patel; Guy W Lloyd; A Neil Sulke
Journal:  J Interv Card Electrophysiol       Date:  2010-01-16       Impact factor: 1.900

6.  [Feasibility and safety of long-term AAI(R) pacing in isolated sinus node syndrome].

Authors:  T Körber; W Voss; B Ismer; F Weber; C A Nienaber; G H von Knorre
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-03

7.  [Avoidance of ventricular pacing in patients with sinus node disease or intermittent AV block].

Authors:  U K H Wiegand
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-03

8.  Non-physiological increase of AV conduction time in sinus disease patients programmed in AAIR-based pacing mode.

Authors:  Philippe Mabo; Jean-Pierre Cebron; Aude Solnon; Aude Tassin; Laurence Graindorge; Daniel Gras
Journal:  J Interv Card Electrophysiol       Date:  2012-07-27       Impact factor: 1.900

9.  A comparison of AAIR versus DDDR pacing for patients with sinus node dysfunction: a long-term follow-up study.

Authors:  Reuben Kato Mutagaywa; Basil Tumaini; Ashley Chin
Journal:  Cardiovasc J Afr       Date:  2020-09-18       Impact factor: 1.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.